

AWARD NUMBER: W81XWH-19-1-0725

TITLE: Assessing Neuroinflammation in Gulf War Illness with Whole-Brain Magnetic Resonance Spectroscopy

PRINCIPAL INVESTIGATOR: Jarred Younger, PhD

CONTRACTING ORGANIZATION: University of Alabama, Birmingham, AL

REPORT DATE: October 2021

TYPE OF REPORT: Annual report

PREPARED FOR: U.S. Army Medical Research and Development Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

# REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

<b>1. REPORT DATE</b> October 2021		<b>2. REPORT TYPE</b> Annual report		<b>3. DATES COVERED</b> 30Sep2020-29Sep2021	
<b>4. TITLE AND SUBTITLE</b>  Assessing Neuroinflammation in Gulf War Illness with Whole-Brain Magnetic Resonance Spectroscopy				<b>5a. CONTRACT NUMBER</b> W81XWH-19-1-0725	
				<b>5b. GRANT NUMBER</b> GW180071	
				<b>5c. PROGRAM ELEMENT NUMBER</b>	
<b>6. AUTHOR(S)</b>  Jarred Younger, PhD  E-Mail: younger@uab.edu				<b>5d. PROJECT NUMBER</b> 0011340886-0001	
				<b>5e. TASK NUMBER</b>	
				<b>5f. WORK UNIT NUMBER</b>	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  University of Alabama at Birmingham UAB 701 20 <sup>th</sup> Street South Birmingham, AL 35294-0001				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b>	
				<b>11. SPONSOR/MONITOR'S REPORT NUMBER(S)</b>	
<b>12. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited					
<b>13. SUPPLEMENTARY NOTES</b>					
<b>14. ABSTRACT</b> Currently, there are no targeted treatments for Gulf War Illness (GWI). In order to solve that problem, it is essential that researchers discover the cause of GWI. It is similarly important that an objective test be developed that can clearly show why individuals suffer from GWI. While many attempts at developing such a test have been made, none of them have yielded a clinically-useful tool. Our central hypothesis is that GWI involves chronic neuroinflammation. The symptoms of GWI (e.g. fatigue, musculoskeletal pain, sleep disturbances, and cognitive dysfunction) overlap heavily with classic cytokine-induced sickness responses. In the case of GWI, microglial cells in the brain can be pushed into a hypersensitized state by toxins or abnormal immune challenges, leading to chronic overproduction of pro-inflammatory factors that result in the primary symptoms of GWI. To test the central hypothesis, it is necessary to measure neuroinflammation in humans in vivo. However, most techniques are too invasive for using in living individuals. To address that problem, we use an MRSI scan which provides metabolite concentrations in 4,000 separate voxels, giving whole-brain coverage. The scan yields measurements for: myo-inositol (a marker of glial cell proliferation), lactate (a product of anaerobic metabolism), choline (a sign of cellular breakdown), and N-acetylaspartate (a marker of neuronal health). The scan also provides absolute brain temperature, which is elevated with severe neuroinflammation.					
<b>15. SUBJECT TERMS</b> Gulf War Illness					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b>	<b>18. NUMBER OF PAGES</b>	<b>19a. NAME OF RESPONSIBLE PERSON</b>
<b>a. REPORT</b>	<b>b. ABSTRACT</b>	<b>c. THIS PAGE</b>			<b>USAMRMC</b>
Unclassified	Unclassified	Unclassified	Unclassified	6	<b>19b. TELEPHONE NUMBER</b> (include area code)

Standard Form 298 (Rev. 8-98)  
Prescribed by ANSI Std. Z39.18

## **TABLE OF CONTENTS**

	<u>Page</u>
<b>1. Introduction</b>	<b>4</b>
<b>2. Keywords</b>	<b>4</b>
<b>3. Accomplishments</b>	<b>4</b>
<b>4. Impact</b>	<b>5</b>
<b>5. Changes/Problems</b>	<b>5</b>
<b>6. Products</b>	<b>5</b>
<b>7. Participants &amp; Other Collaborating Organizations</b>	<b>6</b>
<b>8. Special Reporting Requirements</b>	<b>6</b>
<b>9. Appendices</b>	<b>6</b>

## **Introduction**

The primary objective of this study is to determine if Gulf War Illness (GWI) likely involves neuroinflammation. By assessing the five neuroinflammatory outcomes across the brain, we can determine if there are focal or global signs of one or more neuroinflammatory markers in brains of individuals with GWI. The magnetic resonance spectroscopy imaging (MRSi) technique may allow our group and others to detect cases of GWI neuroinflammation, which would improve treatment decisions as well as the development of new targeted therapies. It is an ideal diagnostic tool because it has low patient risk, is noninvasive, can be used repeatedly in longitudinal studies, provides whole-brain coverage, yields multiple independent markers of inflammation, and can be employed at most hospital and research neuroimaging suites.

## **Keywords**

Gulf War Illness, neuroinflammation, neuroimaging

## **Accomplishments**

### **What were the major goals of the project?**

The major goal of this work is to determine if GWI involves neuroinflammation. Our milestones for study activities are as follows:

	<b>Target Date</b>
Agreement on eligibility criteria, screening protocol, and procedures	July 2019
Consent form and human subjects protocol finalized	July 2019
All UAB, HRPO, and other approvals granted	August 2019
Study protocol ready to begin	August 2019
First participant enrolled	December 2019
20 GWI participants enrolled	May 2022
20 control participants enrolled	June 2022
Results reports generated	August 2022
Report full results from all analyses	August 2022

### **What was accomplished under these goals?**

We received all regulatory approval and were ready to begin enrollment in October 2020. As of now, 17 participants (11 GWI; 6 controls) have been enrolled in the study and completed the protocol. We are currently at 43% of our target enrollment goal. Our recent progress has positioned us to accomplish our enrollment goal of 40 participants by June 2022.

### **What opportunities for training and professional development has the project provided?**

Nothing to report

### **How were the results disseminated to the communities of interest?**

Nothing to report

### **What do you plan to do during the next reporting period to accomplish the goals?**

We plan to conduct radio and digital advertisement campaigns to recruit both healthy and GWI participants. Currently, we have one research coordinator for the study and 2 undergraduate students assisting with the study.

## **Impact**

### **What was the impact on the development of the principal discipline(s) of the project?**

Nothing to report

### **What was the impact on other disciplines?**

Nothing to report

### **What was the impact on technology transfer?**

Nothing to report

### **What was the impact on society beyond science and technology?**

Nothing to report

## **Changes/Problems**

### **Changes in approach and reasons for change**

There have been no changes in approach

### **Actual or anticipated problems or delays and actions or plans to resolve them**

We have recently launched a radio marketing campaign with iHeartMedia, a media company with access to more than 860 radio stations nationwide and over 150 million registered listeners on their digital streaming platform. We have had success with iHeartMedia advertising services in the past for our other clinical studies and are confident that this campaign will bolster enrollment.

### **Changes that had significant impact on expenditures**

We are now able to use funds as originally intended, without restrictions.

### **Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents**

Nothing to report

## **Products**

### **Publications, conference papers, and presentations**

Nothing to report

### **Books or other non-periodical, one-time publications**

Nothing to report

### **Other publications, conference papers, and presentations**

Nothing to report

### **Website**

Nothing to report

### **Technologies or techniques**

Nothing to report

### **Inventions, patent applications, and/or licenses**

Nothing to report

### **Other products**

Nothing to report

**Participants and other collaborating organizations**

<b><u>Name</u></b>	Jarred Younger, PhD	Crystal Taylor, PhD	Chloe Jones
<b><u>Project Role</u></b>	PI	Manager	Study Coordinator
<b><u>Researcher Identifier (ORCID)</u></b>	0000-0003-3616-9919	0000-0001-8359-071X	0000-0002-7288-8235
<b><u>Nearest person month worked</u></b>	2	1	
<b><u>Contribution to project</u></b>	<u>Dr. Younger has developed protocol for execution of study</u>	<u>Dr. Taylor has drafted and submitted all regulatory documents for the study</u>	<u>Chloe has screened and scanned all participants for this study.</u>
<b><u>Funding support</u></b>	<u>AFSA, R01NS109529 (NIH/NINDS), GW1180071 (DOD),</u>	<u>American Fibromyalgia Syndrome Association (AFSA)</u>	<u>UAB</u>

**Has there been a change in the active other support of the PD/PI or senior/key personnel since the last reporting period?**

Yes, there has been a change in the active other support of the PI. The grant entitled "Daily Immune Monitoring in Chronic Fatigue Syndrome" (R01AI107655) ended September 1, 2020.

**What other organizations were involved as partners?**

Nothing to report

**Special reporting requirements**

Nothing to report

**Appendices**

Nothing to report